Assessing Medical Affairs Impact & Value

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Quantifying Impact & Telling the Value Story in Medical Affairs: Scientific Publications, Medical Excellence, Medical Strategy, HEOR/RWE & Patient Focused Initiatives”

STUDY OVERVIEW

While the roles and responsibilities of the Medical Affairs function have significantly increased over the past few years, the qualitative nature of their work often requires Medical leaders to showcase tangible evidence of their impact and value to senior and organizational leadership.

Best Practices LLC undertook benchmarking research to explore how Medical Affairs groups assess the impact and value of each function including Scientific Publications, Medical Excellence, Medical Strategy, HEOR, and Patient-Focused groups. This study probes how the use of external metrics and value-based assessments transforms Medical Affairs functions, enabling Medical professionals to effectively communicate their value to senior leadership.

KEY TOPICS

Assessing Medical Affairs Impact & Value of Each Function

Scientific Publications
Medical Excellence
Medical Strategy
HEOR/RWE
Patient Focused Initiatives

Value Metrics
Impact Metrics
Driving External Impact

KEY METRICS

How valuable are each of the listed Scientific Publications, Medical Excellence, Medical Strategy, HEOR/RWE, and Patient Focused activities to the organization?
How valuable are the listed KPIs to demonstrate the impact of activities among external stakeholders?
How successful have the Scientific Publications, Medical Excellence, Medical Strategy, HEOR/RWE, and Patient Focused groups been in generating measurable, external impact across each of the listed external stakeholder objectives?

SAMPLE KEY FINDINGS

Patient-Focused Impact Metrics: High-impact KPIs to demonstrate value to external stakeholders include:

83%: Recognition of improvement in quality of life
67%: Accelerate time to disease diagnosis
67%: Successful launch support
67%: Share of patient voice

METHODOLOGY

Best Practices LLC engaged 38 Medical Affairs leaders from 31 leading pharmaceutical companies in this research through a benchmarking survey instrument. Deep-dive interviews were also conducted with Medical Affairs leaders at 10 organizations to capture additional insights.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Biopharmaceutical; Medical Device; Manufacturing; Consumer Products; Chemical; Clinical Research; Laboratories

Companies Profiled:
Abbott; Adaptimmune; ASC Therapeutics; Astellas; AstraZeneca; Baxter International; Bayer; bioMerieux; Boehringer Ingelheim; Domp�; Dermavant Sciences; Eisai; Eli Lilly; Genentech; GlaxoSmithKline ; GRAIL; Grifols; Jazz Pharmaceuticals; Merck; Myovant Sciences; Novartis; Novo Nordisk; OTSUKA; Pfizer; Roche; Sage Therapeutics; Sanofi; Santen; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Quantifying Impact & Telling the Value Story in Medical Affairs: Scientific Publications, Medical Excellence, Medical Strategy, HEOR/RWE & Patient Focused Initiatives

ID: 5766

Features:

Pages/Slides: 38

Published: 2023

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6638A976C61849591002589EC003623EE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-quantifying-impact-telling-value-story-in-medical-affairs-scientific-publications-excellence-strategy-heor-rwe-patient-focused-initiatives?opendocument
18
19opendocument
2018.206.194.21
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB